1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Osimertinib, a third-generation irreversible mutant-selective inhibitor of EGFR kinase activity was clinically evaluated in the AURA trials, where it showed high clinical efficacy and a favorable toxicity profile in patients with acquired exon 20-EGFR pT790M mutation. We provide the clinical data of the German expanded access program that further characterizes the efficacy and safety of osimertinib in a heterogeneous patient population outside clinical trials.

          Related collections

          Author and article information

          Journal
          J. Cancer Res. Clin. Oncol.
          Journal of cancer research and clinical oncology
          Springer Science and Business Media LLC
          1432-1335
          0171-5216
          Dec 2018
          : 144
          : 12
          Affiliations
          [1 ] Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital of Frankfurt, Theodor Stern Kai 7, 60596, Frankfurt am Main, Germany. jan.stratmann@kgu.de.
          [2 ] Lung Cancer Group Cologne, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
          [3 ] Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital of Frankfurt, Theodor Stern Kai 7, 60596, Frankfurt am Main, Germany.
          [4 ] Department of Medical Oncology, University Hospital of Essen, Hufelandstr. 55, 45147, Essen, Germany.
          [5 ] Department of Pneumology, Clinic Bremen-Ost, Züricher Str. 40, 28325, Bremen, Germany.
          [6 ] Department of Internal Medicine II, University Hospital of Tübingen, Otfried-Müller-Straße 10, 72076, Tübingen, Germany.
          [7 ] Department of Thoracic Oncology, University Hospital of Heidelberg, Röntgenstr. 1, 69126, Heidelberg, Germany.
          [8 ] Helios Clinic Emil von Behring, Walterhöferstr. 11, 14165, Berlin, Germany.
          [9 ] Department of Internal Medicine III, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.
          [10 ] Department of Hematology and Oncology, University Hospital of Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
          [11 ] Hämato-Onkologie Hamburg, Stader Straße 203c, 21075, Hamburg, Germany.
          [12 ] Department of Pneumology, Clinic Schillerhoehe, Solitudestr. 18, 70839, Gerlingen, Germany.
          [13 ] Department of Hematology and Oncology, Pius Hospital Oldenburg, Georgstraße 12, 26121, Oldenburg, Germany.
          Article
          10.1007/s00432-018-2754-x
          10.1007/s00432-018-2754-x
          30244389
          448d33ed-5e05-427a-98fe-31de0776f5f6
          History

          MET,EGFR,Non-small cell lung cancer,Osimertinib,T790M
          MET, EGFR, Non-small cell lung cancer, Osimertinib, T790M

          Comments

          Comment on this article